Grant: Discovery Grants Program - Individual
University of Guelph
$40,000.00
Prevention and treatment of food allergy by specific glycation and peptide-based oral immunotherapy
EF 2012-13
Résumé
The prevalence of food allergies varies across countries and it ranges 4-8% in children and 1-5% in adults in North America. Earliest allergy cases (onset before the age of 6 months) involve mainly cow's milk and then allergies to egg (2nd most common food allergen). There is currently no treatment for food allergy. However, in children, tolerance can be naturally achieved and some allergies may diminish or disappear with age. The two-third of egg allergy children acquire tolerance at the age of 5 years, however, 35% of children remain allergic throughout their lives. In the previous work, we demonstrated genetically engineered ovomucoid (OVM) (one of major egg allergens) by means of site-directed mutagenesis and glycosylation can modulate allergic responses and induce tolerance in egg allergy mouse model. Furthermore, we reported that orally administered synthetic ovalbumin (OVA) multiple T-cell epitopes can suppress allergic responses in an egg allergy mouse by the elicitation of FoxP3 and TGF-beta associated mechanisms. These glycation and peptide-based immunotherapy represents an attractive approach for targeting interventions in food allergy. In this view, we further study systematic induction of mucosal tolerance of egg allergy using various types of glycation forms of OVA (glucose, D-mannose, glucomannan, , and galactomannan) and peptides derived from OVM depleted heat denatured egg white proteins. Ex-vivo study on antigen uptake and presentation by dendritic cells will be performed. An established egg allergy Balb/c model will be used in vivo study. Gastrointestinal (GI) mucosal immune responses will be characterized by analyzing various biomarkers of serum histamine, specific IgE, IgG, various cytokine secretion, GI local gene expression and CD4 cell analysis. Particularly, Th1, Th2, Th17 and T reg cells and toll like receptor functions are main target in this study. We will examine the mechanism of oral tolerance induction and explore novel immunotherapeutic strategies for treatment and prevention of food allergy.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
184794-2011
Name nom
Mine, Yoshinori
Department département
Food Science
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2012
Competition year année de concours
2011
Award amount
40000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1502
Committee name en
Biological Systems and Functions
Committee name fr
Systèmes et fonctions biologiques
Area of application code
100
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Agriculture and primary food production
Area of application fr
Agriculture et produits alimentaires primaires
Research subject code
6100
Research subject group en
Food science and technology
Research subject group fr
Science et technologie de l'alimentation
Research subject en
Food science and technology
Research subject fr
Science et technologie de l'alimentation
Partie
2
Nb partie
5
Application title
Prevention and treatment of food allergy by specific glycation and peptide-based oral immunotherapy
Keyword
NSERC
Application summary
The prevalence of food allergies varies across countries and it ranges 4-8% in children and 1-5% in adults in North America. Earliest allergy cases (onset before the age of 6 months) involve mainly cow's milk and then allergies to egg (2nd most common food allergen). There is currently no treatment for food allergy. However, in children, tolerance can be naturally achieved and some allergies may diminish or disappear with age. The two-third of egg allergy children acquire tolerance at the age of 5 years, however, 35% of children remain allergic throughout their lives. In the previous work, we demonstrated genetically engineered ovomucoid (OVM) (one of major egg allergens) by means of site-directed mutagenesis and glycosylation can modulate allergic responses and induce tolerance in egg allergy mouse model. Furthermore, we reported that orally administered synthetic ovalbumin (OVA) multiple T-cell epitopes can suppress allergic responses in an egg allergy mouse by the elicitation of FoxP3 and TGF-beta associated mechanisms. These glycation and peptide-based immunotherapy represents an attractive approach for targeting interventions in food allergy. In this view, we further study systematic induction of mucosal tolerance of egg allergy using various types of glycation forms of OVA (glucose, D-mannose, glucomannan, , and galactomannan) and peptides derived from OVM depleted heat denatured egg white proteins. Ex-vivo study on antigen uptake and presentation by dendritic cells will be performed. An established egg allergy Balb/c model will be used in vivo study. Gastrointestinal (GI) mucosal immune responses will be characterized by analyzing various biomarkers of serum histamine, specific IgE, IgG, various cytokine secretion, GI local gene expression and CD4 cell analysis. Particularly, Th1, Th2, Th17 and T reg cells and toll like receptor functions are main target in this study. We will examine the mechanism of oral tolerance induction and explore novel immunotherapeutic strategies for treatment and prevention of food allergy.